Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
49.1M
-
Shares change
-
+2.37M
-
Total reported value, excl. options
-
$1.68B
-
Value change
-
+$93.9M
-
Put/Call ratio
-
0.53
-
Number of buys
-
82
-
Number of sells
-
-50
-
Price
-
$34.20
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2021
176 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2021.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.1M shares
of 62.2M outstanding shares and own 79.04% of the company stock.
Largest 10 shareholders include FMR LLC (6.85M shares), BVF INC/IL (3.65M shares), BlackRock Inc. (3.28M shares), EcoR1 Capital, LLC (2.64M shares), RTW INVESTMENTS, LP (2.6M shares), STATE STREET CORP (2.57M shares), JOHNSON & JOHNSON (2.45M shares), Point72 Asset Management, L.P. (2.42M shares), VANGUARD GROUP INC (2.35M shares), and FARALLON CAPITAL MANAGEMENT LLC (1.92M shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.